{"id":7520,"date":"2025-06-03T15:10:00","date_gmt":"2025-06-03T13:10:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-lyfter-fram-nex-22-och-pharmashell-i-en-intensiv-internationell-exponeringsperiod\/"},"modified":"2025-06-03T15:10:00","modified_gmt":"2025-06-03T13:10:00","slug":"nanexa-lyfter-fram-nex-22-och-pharmashell-i-en-intensiv-internationell-exponeringsperiod","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-lyfter-fram-nex-22-och-pharmashell-i-en-intensiv-internationell-exponeringsperiod\/","title":{"rendered":"Nanexa lyfter fram NEX-22 och PharmaShell\u00ae i en intensiv internationell exponeringsperiod"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Nanexa AB (publ) meddelar idag att bolaget g\u00e5r in i en intensiv period av internationell n\u00e4rvaro d\u00e4r s\u00e4rskilt fokus kommer att ligga p\u00e5 NEX-22 \u2013 bolagets l\u00e5ngverkande formulering av liraglutid baserad p\u00e5 PharmaShell\u00ae-plattformen \u2013 med nya data fr\u00e5n bolagets egenutvecklade drug delivery-teknologi.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>F\u00f6rst ut \u00e4r <strong>Drug Delivery &amp; Formulation (DDF) Summit, Berlin, Tyskland<\/strong>, d\u00e4r Joel Hellrup idag, 3 juni, presenterar \u201c<em>PharmaShell\u00ae \u2013 The high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision<\/em>\u201d.<\/p>\n<p>D\u00e4refter forts\u00e4tter Nanexa sin internationella n\u00e4rvaro vid f\u00f6ljande evenemang:<\/p>\n<ul>\n<li><strong>BIO International Convention\u00a0i Boston, USA<\/strong> \u2013 ett forum f\u00f6r att skapa strategiska partnerskap och licensieringsm\u00f6jligheter (juni)<\/li>\n<li><strong>American Diabetes Association (ADA) Scientific Sessions\u00a0i Chicago, USA<\/strong> \u2013 d\u00e4r bolagets fas I-data f\u00f6r NEX-22 har accepterats som ett Late Breaking Abstract och kommer att presenteras som poster (juni)<\/li>\n<li><strong>Controlled Release Society (CRS) Annual Meeting\u00a0i Philadelphia, USA<\/strong> \u2013 d\u00e4r Nanexa kommer att h\u00e5lla en entimmes muntlig presentation om PharmaShell\u00ae (juli)<\/li>\n<\/ul>\n<p>NEX-22 \u00e4r en m\u00e5nadsdep\u00e5 av GLP-1-analogen liraglutid, utvecklad med PharmaShell\u00ae-teknologin. I den nyligen avslutade fas I-studien visade NEX-22 en dosproportionell \u00f6kning av exponering och en kontrollerad fris\u00e4ttning av l\u00e4kemedlet \u00f6ver en m\u00e5nad efter en enda subkutan injektion. Resultaten st\u00e4rker potentialen f\u00f6r en g\u00e5ng i m\u00e5naden-behandling av typ 2-diabetes och har v\u00e4ckt stort intresse fr\u00e5n potentiella samarbetspartners.<\/p>\n<p>\u201dAtt v\u00e5rt abstract med NEX-22 presenteras p\u00e5 ADA \u00e4r ett viktigt erk\u00e4nnande av v\u00e5ra data,\u201d s\u00e4ger\u00a0David Westberg, vd f\u00f6r Nanexa. \u201dVi ser ocks\u00e5 fram emot att presentera v\u00e5ra framsteg p\u00e5 b\u00e5de BIO och CRS, \u00e4ven i individuella m\u00f6ten med ett flertal intressanta bolag f\u00f6r att diskutera samarbeten. Denna exponeringsperiod \u00e4r ett viktigt steg i v\u00e5r aff\u00e4rsutveckling och st\u00e4rker v\u00e5r position inom diabetes- och obesitasomr\u00e5det och m\u00f6jligg\u00f6r PharmaShell\u00ae som en drug delivery-plattform f\u00f6r s\u00e5v\u00e4l v\u00e4lk\u00e4nda som nya l\u00e4kemedelsmolekyler\u201d.\u00a0<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-2376405b3437\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 vd, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" rel=\"noopener\" target=\"_blank\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" rel=\"noopener\" target=\"_blank\">www.nanexa.com<\/a><\/p>\n<p>Bolagets Certified Adviser \u00e4r DNB Carnegie Investment Bank AB (publ).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-c9ba281e2dde\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/06b68cc0-c4b4-4224-9558-570ad903185b\/nanexa-lyfter-fram-nex-22-och-pharmashell-r-i-en-intensiv-internationell-exponeringsperiod.pdf\" rel=\"noopener\" target=\"_blank\">Nanexa lyfter fram NEX-22 och PharmaShell\u00ae i en intensiv internationell exponeringsperiod<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nanexa AB (publ) meddelar idag att bolaget g\u00e5r in i en intensiv period av internationell n\u00e4rvaro d\u00e4r s\u00e4rskilt fokus kommer att ligga p\u00e5 NEX-22 \u2013 bolagets l\u00e5ngverkande formulering av liraglutid baserad p\u00e5 PharmaShell\u00ae-plattformen \u2013 med nya data fr\u00e5n bolagets egenutvecklade drug delivery-teknologi.<\/p>\n","protected":false},"template":"","class_list":["post-7520","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-ext-nq_sv","mfn-news-tag-mfn-ext-nq-company-announcement_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa lyfter fram NEX-22 och PharmaShell\u00ae i en intensiv internationell exponeringsperiod - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-lyfter-fram-nex-22-och-pharmashell-i-en-intensiv-internationell-exponeringsperiod\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa lyfter fram NEX-22 och PharmaShell\u00ae i en intensiv internationell exponeringsperiod - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB (publ) meddelar idag att bolaget g\u00e5r in i en intensiv period av internationell n\u00e4rvaro d\u00e4r s\u00e4rskilt fokus kommer att ligga p\u00e5 NEX-22 \u2013 bolagets l\u00e5ngverkande formulering av liraglutid baserad p\u00e5 PharmaShell\u00ae-plattformen \u2013 med nya data fr\u00e5n bolagets egenutvecklade drug delivery-teknologi.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-lyfter-fram-nex-22-och-pharmashell-i-en-intensiv-internationell-exponeringsperiod\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-lyfter-fram-nex-22-och-pharmashell-i-en-intensiv-internationell-exponeringsperiod\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-lyfter-fram-nex-22-och-pharmashell-i-en-intensiv-internationell-exponeringsperiod\\\/\",\"name\":\"Nanexa lyfter fram NEX-22 och PharmaShell\u00ae i en intensiv internationell exponeringsperiod - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2025-06-03T13:10:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-lyfter-fram-nex-22-och-pharmashell-i-en-intensiv-internationell-exponeringsperiod\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-lyfter-fram-nex-22-och-pharmashell-i-en-intensiv-internationell-exponeringsperiod\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-lyfter-fram-nex-22-och-pharmashell-i-en-intensiv-internationell-exponeringsperiod\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa lyfter fram NEX-22 och PharmaShell\u00ae i en intensiv internationell exponeringsperiod\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa lyfter fram NEX-22 och PharmaShell\u00ae i en intensiv internationell exponeringsperiod - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-lyfter-fram-nex-22-och-pharmashell-i-en-intensiv-internationell-exponeringsperiod\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa lyfter fram NEX-22 och PharmaShell\u00ae i en intensiv internationell exponeringsperiod - Nanexa AB","og_description":"Nanexa AB (publ) meddelar idag att bolaget g\u00e5r in i en intensiv period av internationell n\u00e4rvaro d\u00e4r s\u00e4rskilt fokus kommer att ligga p\u00e5 NEX-22 \u2013 bolagets l\u00e5ngverkande formulering av liraglutid baserad p\u00e5 PharmaShell\u00ae-plattformen \u2013 med nya data fr\u00e5n bolagets egenutvecklade drug delivery-teknologi.","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-lyfter-fram-nex-22-och-pharmashell-i-en-intensiv-internationell-exponeringsperiod\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-lyfter-fram-nex-22-och-pharmashell-i-en-intensiv-internationell-exponeringsperiod\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-lyfter-fram-nex-22-och-pharmashell-i-en-intensiv-internationell-exponeringsperiod\/","name":"Nanexa lyfter fram NEX-22 och PharmaShell\u00ae i en intensiv internationell exponeringsperiod - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2025-06-03T13:10:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-lyfter-fram-nex-22-och-pharmashell-i-en-intensiv-internationell-exponeringsperiod\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-lyfter-fram-nex-22-och-pharmashell-i-en-intensiv-internationell-exponeringsperiod\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-lyfter-fram-nex-22-och-pharmashell-i-en-intensiv-internationell-exponeringsperiod\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa lyfter fram NEX-22 och PharmaShell\u00ae i en intensiv internationell exponeringsperiod"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7520","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7520"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}